• Lenz Therapeutics outlined commercialization for VIZZ, its FDA-approved aceclidine eye drop for presbyopia, positioning it as a once-daily product with effect lasting up to 10 hours.
• US launch planned around a 100+ person sales force targeting about 15,000 eye care professionals, supported by direct-to-consumer advertising featuring Sarah Jessica Parker.
• Pricing set at USD 79 for a 1-month supply of 25 vials; USD 198 for a 3-month supply of 75 vials; cash-pay model with no prior authorization required.
• Management framed US market opportunity at more than USD 3 billion, citing 128 million US presbyopes.
• Cash balance about USD 258 million as of Q1 2026; US new chemical entity exclusivity through 2030; eight granted US patents extending to 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.